the government of Nigeria has alot of faith in this company. google Xechem and Olusegun Obasanjo (Nigeria's President) and you will see he mentions Xechem in his 2005 budget speech. (use the cache feature! it highlights what you are looking for..but you knew that!)
also google Professor Nwosu (the Minister of Health) and Xechem. he is keen on Nicosan, the drug to which Xechem was granted exclusive right to manufacture and sell worldwide.
why was Xechem given this? i don't know...there was a backlash to this (or so i learned from the internet) and you would expect such a thing if the drug was for real.
since Nicosan doesn't cure sickle cell disease, only treat it, the revenue stream looks very attractive.
not bad for 1.4 cents a share and only 260,000,000 or so shares outstanding, if you ask me.
Posts: 393 | Registered: Jul 2003
| IP: Logged |
Xechem International, Inc. (XKEM) Xechem International announced today that its wholly owned subsidiary, Xechem UK Ltd., has received Orphan Drug designation from the European Medicine Evaluation Agency (EMEA) for NIPRISAN (now known as NICOSAN(TM)/HEMOXIN(TM)), a phytopharmaceutical product that has shown efficacy in the treatment of Sickle Cell Disease. The designation covers all 25 countries that comprise the European Union. Similar Orphan Drug status was previously granted to Xechem by the U.S. Food and Drug Administration.
Dr. Ramesh Pandey, Xechem's Chairman & CEO said, "Obtaining Orphan Drug status for our Sickle Cell Disease product in both the European Union and the United States brings to Xechem substantial advantages and incentives which will help facilitate approval of the drug and make it easier for us to bring this important medicine to market. To have received these coveted designations from both the FDA and EMEA for a natural, herb-based product such as ours is particularly gratifying."
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
Xechem International, Inc. (XKEM) Xechem International announced today that it has acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU), Richmond, VA. Early research has shown this anti-sickling agent to be a highly effective and relatively non-toxic treatment for Sickle Cell Disease (SCD). The new compound further expands Xechem's existing portfolio of products to be used in the fight against Sickle Cell Disease.
Previously, Xechem International successfully acquired the exclusive worldwide license from the National Institute for Pharmaceutical Research and Development ("NIPRD"), Ministry of Health, Government of Nigeria, for the manufacture, marketing and distribution of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has also shown enormous promise for SCD. Both the United States Food and Drug Administration (FDA) and the European Union's regulatory body have already granted to Xechem "Orphan Drug" status for NICOSAN(TM)/HEMOXIN(TM), and the Company is currently in the process of preparing an Investigational New Drug (IND) Application for submission to the FDA and applicable EU agencies.
According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "We know of no existing non-toxic medicines available anywhere in the world for the effective treatment of Sickle Cell Disease. Between our existing product, NICOSAN(TM)/HEMOXIN(TM), a non-toxic product that has shown excellent results in Phase IIA and Phase IIB clinical trials in Nigeria, and this promising new heterocyclic pharmaceutical agent being developed in collaboration with VCU, Xechem will be in a truly unique position to offer viable and efficacious treatments to patients suffering with this painful and debilitating condition."
Professor Don Abraham of VCU says that "the five membered heterocyclic compound (5-HMF) is the best potential antisickling agent in 30 years research to be discovered by our research group. 5-HMF not only is a natural product with very little if any toxicity, it has a high affinity for hemoglobin and was very active in genetically modified mice as shown by our colleagues, Dr. Osheiza Abdulmalik and Professor Toshio Asakura, the Director of the NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania. A number of us, especially my very close colleagues at VCU, Professors Martin Safo and Gajanan Joshi, have spent most of our lives searching for a sickle cell drug and we are hoping that this quest is finally achieved."
Sickle Cell Disease is a genetic blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped cells that do not flow freely through blood vessels, creating clogs in the vessels, which in turn cut off the flow of normal hemoglobin and oxygen to the body. In Nigeria alone, more than 25% of the population are carriers of the SCD trait and over 4.5 million Nigerians (approximately 5% of the population) are actually afflicted with the disease. Approximately 12 million people, mostly in sub-Saharan Africa, are believed to suffer from this disease worldwide.
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
